Related references
Note: Only part of the references are listed.Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity
Viralkumar Davra et al.
CANCER RESEARCH (2021)
Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade
Julia Boshuizen et al.
CANCER RESEARCH (2021)
Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation
Enrique J. Arenas et al.
NATURE COMMUNICATIONS (2021)
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Aleix Prat et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
Naoko Okura et al.
CLINICAL CANCER RESEARCH (2020)
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Fara Braso-Maristany et al.
NATURE COMMUNICATIONS (2020)
ERBB2mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
Gaia Griguolo et al.
CANCERS (2020)
FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease
Susana Garcia-Recio et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
TP-0903 is active in models of drug-resistant acute myeloid leukemia
Jae Yoon Jeon et al.
JCI INSIGHT (2020)
AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells
Donghwa Kim et al.
CELL DEATH & DISEASE (2019)
AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
Stephane Terry et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric Study
Shin-Ae Kang et al.
CLINICAL CANCER RESEARCH (2019)
New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer
Anushka Dongre et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Hirokazu Taniguchi et al.
NATURE COMMUNICATIONS (2019)
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Jiani Wang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers
Jing Wei et al.
CELLULAR IMMUNOLOGY (2018)
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
Julia Boshuizen et al.
NATURE MEDICINE (2018)
The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression
Marie-Anne Goyette et al.
CELL REPORTS (2018)
Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis
Wilhem Leconet et al.
CLINICAL CANCER RESEARCH (2017)
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
Antonio Llombart-Cussac et al.
LANCET ONCOLOGY (2017)
Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies
Marie Schoumacher et al.
CURRENT ONCOLOGY REPORTS (2017)
Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer
Triparna Sen et al.
CLINICAL CANCER RESEARCH (2017)
AXL-Driven EMT State as a Targetable Conduit in Cancer
Jane Antony et al.
CANCER RESEARCH (2017)
Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy
Maurizio Scaltriti et al.
CLINICAL CANCER RESEARCH (2016)
The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer
Jane Antony et al.
SCIENCE SIGNALING (2016)
Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance
Miles A. Miller et al.
CANCER DISCOVERY (2016)
Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3 beta/beta-catenin Signaling
Cun Wang et al.
THERANOSTICS (2016)
The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer
Jane Antony et al.
SCIENCE SIGNALING (2016)
AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
Moshe Elkabets et al.
CANCER CELL (2015)
Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia
I-K Park et al.
LEUKEMIA (2015)
Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
Rocio Vicario et al.
PLOS ONE (2015)
Mesenchymal Cancer Cell-Stroma Crosstalk Promotes Niche Activation, Epithelial Reversion, and Metastatic Colonization
Yaiza del Pozo Martin et al.
CELL REPORTS (2015)
AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells
M. K. Asiedu et al.
ONCOGENE (2014)
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
Judith Mueller et al.
NATURE COMMUNICATIONS (2014)
An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers et al.
CLINICAL CANCER RESEARCH (2013)
Molecular Mechanism of 17-Allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL Receptor Tyrosine Kinase Degradation
Gnana Prakasam Krishnamoorthy et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Vimentin as a poor prognostic factor for triple-negative breast cancer
Nami Yamashita et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival
Smita Salian-Mehta et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2013)
The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells
Aaron S. Meyer et al.
SCIENCE SIGNALING (2013)
Axl is essential for VEGF-A-dependent activation of PI3K/Akt
Guo-Xiang Ruan et al.
EMBO JOURNAL (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer
Toru Mukohara
CANCER SCIENCE (2011)
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer
K. Vuoriluoto et al.
ONCOGENE (2011)
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
Balazs Gyoerffy et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity
Amy K. Keating et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival
Christine Gjerdrum et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
Li Liu et al.
CANCER RESEARCH (2009)
Epithelial-Mesenchymal Transitions in development and disease: old views and new perspectives
M. Angela Nieto
INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY (2009)
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
M. M. Moasser
ONCOGENE (2007)
Bone marrow cells in the 'pre-metastatic niche': within bone and beyond
Rosandra N. Kaplan et al.
CANCER AND METASTASIS REVIEWS (2006)
Share Paper
